SCHEMBL2279563

SCHEMBL2279563

Fc1cccc(Nc2cc(Cl)ncn2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPK1 P28482 2/20 0.56
HTT P42858 2/20 0.56
KDM4E B2RXH2 1/20 0.56
LMNA P02545 1/20 0.56
MAPK10 P53779 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NPC1 O15118 2/20 0.51
EGFR P00533 9/20 0.49
RAB9A P51151 2/20 0.49
ABCG2 Q9UNQ0 1/20 0.49
ALDH1A1 P00352 1/20 0.49
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47
ERBB2 P04626 2/20 0.47
ERBB3 P21860 2/20 0.47
MKNK1 Q9BUB5 2/20 0.46
MAPT P10636 1/20 0.46
FGFR1 P11362 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3952295 0.83 EGFR (0.66) MEN1KMT2AHTTKDM4ENPC1
Hydrochloric Acid SCHEMBL2173883 0.82 EGFR (0.64) MEN1KMT2AHTTKDM4ENPC1
SCHEMBL22328022 0.81 NPC1 (0.64) MEN1KMT2AMAPK1LMNAMAPK10
SCHEMBL857502 0.81 NPC1 (0.63) MEN1KMT2AMAPK1LMNANPC1
SCHEMBL657571 0.81 TP53 (0.62) HTTNPC1EGFRABL1ERBB3
SCHEMBL12510600 0.81 NPC1 (0.51) MEN1KMT2ANPC1EGFRRAB9A
SCHEMBL691533 0.81 EGFR (0.57) NPC1EGFRABCG2ERBB3
SCHEMBL2389236 0.81 MEN1 (0.56) MEN1KMT2AMAPK1HTTKDM4E
SCHEMBL20093470 0.81 NPC1 (0.51) MEN1KMT2AKDM4ELMNANPC1
SCHEMBL2279629 0.81 EGFR (0.59) HTTNPC1EGFRERBB3MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2519501-B1 SUBSTITUTED PYRIDINES AND PYRIMIDINES FOR THE PRODUCTION OF CARDIOMYOCYTE-LIKE CELLS UNIV WIEN TECH (AT) 2015-04-22 EP disclosed
US-8986994-B2 Substituted pyridines and pyrimidines TECHNISCHE UNIVERSITAET WIEN (AT) 2015-03-24 US disclosed
US-8986994-B2 Substituted pyridines and pyrimidines TECHNISCHE UNIVERSITAET WIEN (AT) 2015-03-24 US disclosed
US-20120329784-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC 2012-12-27 US disclosed
US-20120294835-A1 SUBSTITUTED PYRIDINES AND PYRIMIDINES MEDIZINISCHE UNIVERSITAET WIEN (AT) 2012-11-22 US disclosed
US-20120294835-A1 SUBSTITUTED PYRIDINES AND PYRIMIDINES MEDIZINISCHE UNIVERSITAET WIEN (AT) 2012-11-22 US disclosed
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed
WO-2011079343-A2 SUBSTITUTED PYRIDINES AND PYRIMIDINES TECHNISCHE UNIVERSITAET WIEN (AT) 2011-07-07 WO disclosed
US-7291730-B2 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-11-06 US disclosed
US-20050107609-A1 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY 2005-05-19 US disclosed
US-6838463-B2 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-01-04 US disclosed
EP-1366026-B1 PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-20040077669-A1 Pyrimidine compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-04-22 US disclosed
EP-1366026-A2 PYRIMIDINE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2003-12-03 EP disclosed
WO-2002024663-A2 PYRIMIDINE COMPOUNDS AND THEIR USE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107609-A1 Pyrimidine compounds and their use TYMP, TYMS, UMPS MEN1 2555/4885KMT2A 2406/4885MAPK1 2068/4885
US-20040077669-A1 Pyrimidine compounds and their use TYMP, TYMS, DPYD MEN1 2039/4885KMT2A 1917/4885MAPK1 1924/4885
US-20120329784-A1 COMPOUNDS AND METHODS RB1, DHFR, NQO1 MEN1 426/4885KMT2A 2469/4885MAPK1 3889/4885
US-20120294835-A1 SUBSTITUTED PYRIDINES AND PYRIMIDINES TNNI3, TNNT2, PROX1 MEN1 4740/4885KMT2A 2502/4885MAPK1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.